Xiamen C&D
厦门建发
Xiamen C&D appears in elsewhere's corpus mostly alongside Qiming Venture Partners, in two roles. As an LP: it was among the existing LPs in Qiming's sixth RMB fund, the record 6.5 billion yuan raise reported by 暗涌Waves in May 2023 . As a direct co-investor in healthcare: it followed into Changsen Pharma's Series B+ round (hundreds of millions of yuan, led by Qiming, October 2025) , and participated in the C+ round of Medway Medical (宏济医疗), led by Fengnian Capital, per Qiming's March 2026 announcement .
Beyond these investment footprints, the corpus carries no profile of Xiamen C&D itself — its background, scale, or broader strategy are not covered.
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners Exclusively Leads Medway Medical's Series C Financing
a leading player in China's disposable endoscope market
Qiming Star | Changsen Pharma Raises Hundreds of Millions of Yuan in Series B+ Funding to Accelerate Clinical Research and Global Expansion of Core Pipeline
Changsen Pharma is dedicated to independently developing first-in-class, best-in-class innovative drugs with global intellectual property rights to address unmet clinical needs.
Jingneng Microelectronics has completed its Series A funding round, led by Gaorong Ventures.
Advancing the design, R&D, manufacturing, and application of power semiconductors.
Qiming Venture Partners Raises Record 6.5 Billion RMB; Duane Kuang: Scale Was Not the Goal
2020 was a watershed year.
3 Billion New Fund First Close: Arthur Yeung on Kairous Capital's Two Major Organizational Restructurings
A New Solution to the Organizational Challenge of Funds.
Gaorong Monthly · December | Gaorong Ventures and Its Frontier Tech / Consumer / Healthcare / Enterprise Service Portfolio Companies Win Multiple Annual Awards
Its technological and innovative capabilities have won recognition.
Chuanwazi Foods Raises Nearly RMB 300 Million in Series A Funding, Aiming to Become China's Go-To Brand for Fresh Sauce
Bold and zesty, there for every meal.
